drugset

drugset / Trial / NCT04120987

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

NCT04120987 ↗

Phase 4 Withdrawn Bucci Laser Vision Institute

RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.

Timeline

Start: 2021-05-31
Primary completion: 2022-06-25
Completion: 2022-06-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Lifitegrast	Unknown	5 %	Other

Indications